
About Longeveron
Longeveron is a publicly listed company based in Miami (United States) founded in 2014 by Joshua M Hare. Cellular therapies for aging-related and life-threatening conditions are developed. Longeveron has raised $1.05 million across 9 funding rounds from investors including NIH, HHS and TEDCO. The company has 26 employees. Longeveron offers products and services including Lomecel-B. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Neurology. Its legal entity is LONGEVERON INC. Its competitors include T3D Therapeutics, Alzheon and Totus Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Longeveron was founded in 2014 in Miami, United States, within the biotechnology sector focused on cellular therapies. Operations center on the development of treatments derived from culture-expanded medicinal signaling cells sourced from adult human bone marrow donors. The lead candidate, Lomecel-B, is targeted at conditions including aging frailty, Alzheimers disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
- Headquarters Miami, United States
- Employees 26
- Founders Joshua M Hare
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website longeveron.com
- Social LinkedIn Instagram YouTube
- Legal Name Longeveron Inc.
- Annual Revenue$1.2 M (USD)-49.87as on Dec 31, 2025
- Net Profit-$22.7 M (USD)-42.14as on Dec 31, 2025
- EBITDA-$22.06 M (USD)-41.75as on Dec 31, 2025
- Total Equity Funding$1.05M (USD)
in 9 rounds
- Latest Funding Round$15M (USD), Post-IPO
Mar 2026
- InvestorsNIH
& 7 more
- Employee Count26
Products & Services of Longeveron
Longeveron offers a comprehensive portfolio of products and services, including Lomecel-B.
Stem cell-based treatment for heart and neurodegenerative diseases
Apps and channels of Longeveron
its YouTube channel Benzinga Events has 3.41K subscribers and 30 videos.
Videos from Longeveron
The most watched videos on Longeveron's YouTube channel, Benzinga Events (3.41K subscribers). Click a video to play it here.
More on Benzinga Events.
Funding Insights of Longeveron
Longeveron has successfully raised a total of $1.05M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.05M
- Total Rounds 9
- Last Round Post-IPO β $15M
- First Round $750,000
(May 2017)
- Investors Count 8
All 9 funding rounds of Longeveron with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $15M | Post-IPO | β | β | |
| Dec 2021 | $20.46M | Post-IPO | β | β | β |
| Feb 2020 | $100,000 | Seed | β | β | β |
| Nov 2018 | $6.7M | Grant | β | β | |
| Oct 2018 | $3.8M | Grant | β | β | |
| Sep 2018 | $4.24M | Grant | β | β | |
| Oct 2017 | $954,970 | Seed | β | β | β |
| Sep 2017 | $1.05M | Grant | β | β | |
| May 2017 | $750,000 | Grant | β | β |
8 investors in total: 8 institutional.
Investors in Longeveron
Longeveron has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and TEDCO.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund and startup accelerator programs focused on seed and early stage companies | 1998 | tedcomd.com | Columbia, United States | |
Stem cell research startups in healthcare are funded and accelerated. | mscrf.org | Columbia, United States | ||
| janushenderson.com | ||||
| logoscapital.com | ||||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| coastlandscapital.com | ||||
| kalehuacapital.com |
Investor details for Longeveron
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Longeveron
25 people are tracked at Longeveron (7 in leadership, 12 in board & advisors, 6 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
Joshua M Hare | Co-Founder | Leadership |
Wa'el Hashad | CEO | Leadership |
Lisa McClain-Moss | VP, Manufacturing | Leadership |
Heather Zhou | Vice President & Corporate Controller | Leadership |
Lisa Locklear | CFO | Leadership |
Nataliya Agafonova | Chief Medical Officer | Leadership |
Jen Dumas | Vice President, Human Resources | Leadership |
Jeffrey Pfeffer | Director | Board & advisors |
Khoso Baluch | Director | Board & advisors |
Erin Borger | Director | Board & advisors |
Hidenori Arai | Advisor | Board & advisors |
Elena Volpi | Advisor | Board & advisors |
Ursula Ungaro | Director | Board & advisors |
Douglas Losordo | Director | Board & advisors |
Jeremy D. Walston | Advisor | Board & advisors |
Donald M. Soffer | Director | Board & advisors |
Cathy Ross | Director | Board & advisors |
Joe G. N. Garcia | Advisor | Board & advisors |
Rock Soffer | Director | Board & advisors |
Michael Brown | Senior Manufacturing Associate & Team Lead | Team |
5 more people are available in the full profile.
Complete people profiles for Longeveron
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Longeveron
Longeveron is a publicly listed company on the NASDAQ with ticker symbol LGVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Feb 2021
- Listed onNASDAQ: LGVN
- Listed entityLongeveron Inc.
- Exchange sectorHealth technology
- ISINUS54303L3024
- Share price$2.15 (-12.24% on the day) · 2026-10-13
- Market capitalisation$6.9M
- EPS (diluted, trailing year)$-10.15
- Volume (last session)60,522
Financials of Longeveron
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.2M | -$22.7M | -$22.1M |
| 2024 | $2.4M | -$16.0M | -$15.6M |
| 2023 | $709,000 | -$21.4M | -$19.7M |
| 2022 | $1.2M | -$18.8M | -$17.1M |
| 2021 | $1.3M | -$17.1M | -$16.5M |
Detailed financial statements for Longeveron
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Longeveron
4 dated milestones of Longeveron across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Longeveron is founded.
- Funding First funding round of $750K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $15.0M.
Competitors of Longeveron
Longeveron has 3 listed competitors in our database, 3 of them funded. They include T3D Therapeutics, Alzheon and Totus Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| t3dtherapeutics.com | 2013 | Durham, United States | $33.02M | Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed. | ||
| alzheon.com | 2013 | Framingham, United States | $195.25M | Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed. | ||
| totusmedicines.com | 2019 | Cambridge, United States | $106M | 23 | Genome-scale drug discovery platform is provided for treating multiple diseases. |
Detailed competitors of Longeveron
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Longeveron
The website of Longeveron (longeveron.com) receives about 3.1K visits a month and ranks #3,823,999 among all websites worldwide, #4,881 in Biotechnology and Pharmaceuticals.
- Monthly visits3.1K
▼ 43.5% vs previous month
- Unique visitors2.1K
per month
- Global rank#3,823,999
among all websites
- Category rank#4,881
Health · Biotechnology and Pharmaceuticals
- Bounce rate54%
- Pages per visit1.4
- Average visit16 sec
- DevicesDesktop 48% Β· Mobile 52%
Top companies in Pulmonology
3 companies that operate in the same segment as Longeveron (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Longeveron
Complete news archive for Longeveron
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Longeveron
Longeveron was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Longeveron is headquartered in Miami, United States. It is registered at Miami, Florida, United States.
Longeveron is a funded company, having raised a total of $1.05M across 9 funding rounds to date. The company's 1st funding round was a Grant of $750K, raised on May 2017.
Longeveron has 26 employees.
Annual revenue of Longeveron is $1.2M as on Dec 31, 2025.
Longeveron was founded in 2014 in Miami, United States, within the biotechnology sector focused on cellular therapies. Operations center on the development of treatments derived from culture-expanded medicinal signaling cells sourced from adult human bone marrow donors. The lead candidate, Lomecel-B, is targeted at conditions including aging frailty, Alzheimers disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
Longeveron's top competitors include Alzheon, Totus Medicines and T3D Therapeutics.
Longeveron offers Lomecel-B.
Yes, Longeveron is publicly traded on NASDAQ under the ticker symbol LGVN.
Longeveron has 8 investors. Key investors include NIH, HHS, TEDCO, Maryland Stem Cell Research Fund, and Coastlands Capital.
Longeveron operates through Longeveron Inc..
